KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $10.3 million.

  • Halozyme Therapeutics' Depreciation & Amortization (CF) rose 3.85% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 2.34%. This contributed to the annual value of $10.3 million for FY2024, which is 7.21% down from last year.
  • Halozyme Therapeutics' Depreciation & Amortization (CF) amounted to $10.3 million in FY2024, which was down 7.21% from $11.1 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) peaked at $11.1 million during FY2023, and registered a low of $3.0 million during FY2021.
  • For the 3-year period, Halozyme Therapeutics' Depreciation & Amortization (CF) averaged around $9.3 million, with its median value being $10.3 million (2024).
  • In the last 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) decreased by 19.51% in 2020 and then soared by 116.67% in 2022.
  • Halozyme Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $3.3 million in 2020, then declined by 9.09% to $3.0 million in 2021, then skyrocketed by 116.67% to $6.5 million in 2022, then skyrocketed by 70.77% to $11.1 million in 2023, then decreased by 7.21% to $10.3 million in 2024.